Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of a Vaccine in Combination with Beta-glucan in People with Neuroblastoma

Trial Status: active

This phase II trial tests the effectiveness of bivalent vaccine, saponin-based immunoadjuvant OBI-821 (OPT-821 [QS-21]), in combination with beta-glucan in treating patients with neuroblastoma that has a higher chance of coming back or resisting standard treatment (high-risk). A bivalent vaccine, such as OPT-821 (QS-21), works by stimulating an immune response against two different antigens, which are specific proteins on the surface of a cell. OPT-821 (QS-21) stimulates an immune response against GD2L and GD3L that are found on neuroblastoma cells and trains the immune system to make antibodies against them. Beta-glucan is a kind of sugar from yeast and may help white blood cells kill tumor cells. Giving OPT-21 (QS-21) vaccine in combination with beta-glucan may kill more tumor cells in patients with high-risk neuroblastoma.